Literature DB >> 10021301

Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology.

L J Bollen1, S P Tjong-A-Hung, J van der Velden, B W Mol, F W ten Kate, J ter Schegget, O P Bleker.   

Abstract

To determine the discriminative capacity of human papillomavirus (HPV) DNA testing for recurrent and residual cervical dysplasia, 43 patients with abnormal cytology after treatment for cervical dysplasia were tested for the presence of HPV DNA by PCR. An endocervical curettage was performed in all patients for histological examination. Sixteen of the 43 patients showed moderate or severe dysplasia. The HPV test was positive in all 16 patients with recurrent or residual dysplasia and negative in 12 of the 27 patients without dysplasia. The sensitivity and specificity of the HPV test were 100 and 44%, respectively. The likelihood ratio of a positive HPV test was 1.8, whereas a negative HPV test had a likelihood ratio of 0.12. Testing for the presence of HPV has the potential to select patients without recurrent or residual cervical dysplasia who have an abnormal cytological smear. This may have clinical implications, since unnecessary diagnostic conizations may be avoided in patients with abnormal cytology after treatment for cervical dysplasia and a negative HPV test. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10021301     DOI: 10.1006/gyno.1998.5250

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

Review 1.  Cervical cytology after 2000: where to go?

Authors:  C J Meijer; J M Walboomers
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

2.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

3.  Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies.

Authors:  R Tachezy; I Mikysková; V Ludvíková; L Rob; T Kucera; V Slavík; A Beková; H Robová; M Pluta; E Hamsíková
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

Review 4.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.

Authors:  Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

Review 5.  Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.

Authors:  Sarah R Hoffman; Tam Le; Alexandre Lockhart; Ayodeji Sanusi; Leila Dal Santo; Meagan Davis; Dana A McKinney; Meagan Brown; Charles Poole; Corinne Willame; Jennifer S Smith
Journal:  Int J Cancer       Date:  2017-02-27       Impact factor: 7.396

6.  High trait shame undermines the protective effects of prevalence knowledge on state shame following HPV/CIN diagnosis in women.

Authors:  Sarah McQueary Flynn; Tory A Eisenlohr-Moul; Suzanne C Segerstrom; Christen T Logue; Jamie L Studts
Journal:  J Behav Med       Date:  2017-04-17

7.  Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?

Authors:  Björn Strander; Walter Ryd; Keng-Ling Wallin; Bengt Wärleby; Biying Zheng; Ian Milsom; Baback Gharizadeh; Nader Pourmand; Agneta Andersson-Ellström
Journal:  Eur J Cancer       Date:  2007-07-05       Impact factor: 9.162

8.  Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study.

Authors:  M J Huchko; V G Woo; T Liegler; H Leslie; K Smith-McCune; G F Sawaya; E A Bukusi; C R Cohen
Journal:  BJOG       Date:  2013-05-07       Impact factor: 6.531

9.  Scientific issues related to the cytology proficiency testing regulations.

Authors:  George Birdsong; Lydia Howell; Karen Atkison; R Marshall Austin; Marluce Bibbo; Thomas A Bonfiglio; Diane D Davey; Catherine Keebler; Dina Mody; Lynnette Savaloja; Jacalyn Papillo; Marianne Prey; Stephen Raab; Brenda L Schultz; Diane Solomon
Journal:  Cytojournal       Date:  2006-04-18       Impact factor: 2.091

10.  Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia.

Authors:  M A Nobbenhuis; C J Meijer; A J van den Brule; L Rozendaal; F J Voorhorst; E K Risse; R H Verheijen; T J Helmerhorst
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.